Siremadlin succinate is under clinical development by Novartis and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). According to GlobalData, Phase II drugs for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Siremadlin succinate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Siremadlin succinate overview
Siremadlin succinate (HDM-201) is under development for the treatment of wild type TP53 characterized advanced or metastatic solid tumors, hematological tumors including acute lymphocytic leukemia, secondary acute myeloid leukemia, acute myelocytic leukemia, myelodysplastic syndrome, metastatic colorectal cancer, metastatic uveal melanoma, dedifferentiated liposarcoma well differentiated liposarcoma and primary myelofibrosis including post-essential thrombocythemia (ET) (PET-MF) and post-polycythemia vera (PV) myelofibrosis (PPV-MF). The small molecule is administered orally and targets HDM2/P53. HDM2 (human double minute 2) is a human homolog of MDM2 (murine double minute 2). it was also under development for the treatment of newly diagnosed acute myeloid leukemia, relapsed and refractory acute myeloid leukemia.
Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.
For a complete picture of Siremadlin succinate’s drug-specific PTSR and LoA scores, buy the report here.